Autopsy report · NCT07057089
Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)
Cause of deathDrug or device supply
“Suspended due to lack of drug supply: the manufacturer ceased to provide investigational drug supply.”
Life of this trial
- Suspended: paused, and may or may not restart.
- 90 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 2
- Sponsor
- Hebei Medical University Fourth Hospital
- Sponsor type
- University, hospital or other
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- Capecitabine; Camrelizumab; CAPOX; Involve-field irradiation; Elective nodal irradiation; TME surgery
- Participants
- 90 (planned, not actual)
- Sites
- 1
- Countries
- China
Trials that died the same way
- A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis
“Drug manufacturer ceased operations” - Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)
“Study suspended in October 2017 and terminated April 17, 2018 after decision to discontinue the study drug development” - Study of XL418 in Adults With Solid Tumors
“Enrollment suspended due to low drug exposure.” - Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
“Sponsor suspended development of the drug on September 3, 2008.” - BEACH Trial: Bovine Early Access, Compatibility and Hemostasis Trial
“Company was sold and clinical trial was suspended then teminated”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.